机构:[1]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China研究所北京市神经外科研究所首都医科大学附属天坛医院[2]Neurological Imaging Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China重点科室诊疗科室研究所神经病学中心神经病学中心北京市神经外科研究所首都医科大学附属天坛医院[3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[4]Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing, China[5]Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China医技科室核医学科首都医科大学附属天坛医院[6]Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China[7]China National Clinical Research Center for Neurological Diseases, Beijing, China[8]Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA)[9]National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China
Unravelling the heterogeneity is the central challenge for glioma precession oncology. In this study, we extracted quantitative image features from T2-weighted MR images and revealed that the isocitrate dehydrogenase (IDH) wild type and mutant lower grade gliomas (LGGs) differed in their expression of 146 radiomic descriptors. The logistic regression model algorithm further reduced these to 86 features. The classification model could discriminate the two types in both the training and validation sets with area under the curve values of 1.0000 and 0.9932, respectively. The transcriptome-radiomic analysis revealed that these features were associated with the immune response, biological adhesion, and several malignant behaviors, all of which are consistent with biological processes that are differentially expressed in IDH wild type and IDH mutant LGGs. Finally, a prognostic signature showed an ability to stratify IDH mutant LGGs into high and low risk groups with distinctive outcomes. By extracting a large number of radiomic features, we identified an IDH mutation-specific radiomic signature with prognostic implications. This radiomic signature may provide a way to non-invasively discriminate lower-grade gliomas as with or without the IDH mutation.
基金:
Beijing Natural Science FoundationBeijing Natural Science Foundation [7174295]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81601452]; Beijing Postdoctoral Research FoundationChina Postdoctoral Science Foundation [2016ZZ-37]; National Basic Research Program of ChinaNational Basic Research Program of China [2015CB755500]; National Key Research and Development Plan [2016YFC0902500]